Amyloidosis does not directly cause Alzheimer’s disease, but Alzheimer’s is itself a form of amyloidosis. Both conditions involve the buildup of misfolded proteins called amyloids, yet the specific proteins, the organs affected, and the disease processes are distinct. The confusion is understandable because the word “amyloid” appears in both, and the underlying biology shares a common thread: proteins that fold incorrectly and clump together in ways that damage tissue.
How Amyloidosis and Alzheimer’s Are Related
Amyloidosis is a broad clinical term for any condition in which amyloid fibrils accumulate in organs and cells, eventually impairing function. It can be hereditary or acquired and is divided into two main categories: systemic amyloidosis, where deposits spread throughout the body (heart, kidneys, nerves), and localized amyloidosis, where deposits form in a single tissue. Alzheimer’s disease falls into the localized category. The amyloid deposits in Alzheimer’s are confined to the brain.
What makes these conditions different at the molecular level is the protein involved. In Alzheimer’s, the culprit is a small peptide called amyloid beta, produced when a larger protein in brain cell membranes gets cut by enzymes. In the most common form of systemic amyloidosis, the protein is either an antibody fragment (in AL amyloidosis) or transthyretin, a transport protein made by the liver. Wild-type transthyretin amyloidosis may affect as much as 25% of people over age 80, but its deposits accumulate in the heart and peripheral nerves, not the brain’s cognitive centers. About a third of patients with systemic amyloidosis die from heart failure caused by amyloid deposits in cardiac tissue.
So while Alzheimer’s and systemic amyloidosis share the same basic problem (misfolded proteins forming damaging clumps), they involve different proteins acting in different organs through different disease pathways.
What Actually Causes Alzheimer’s
Alzheimer’s disease develops when amyloid beta peptides aggregate into plaques between brain cells, triggering a cascade that includes the formation of tangled fibers of another protein, called tau, inside neurons. The 2024 Alzheimer’s Association diagnostic criteria define Alzheimer’s as a biological process first detectable through biomarkers that reflect both amyloid plaques and tau tangles, not amyloid alone. Research using transgenic mice has shown that amyloid beta accelerates the formation of tau tangles, suggesting the two pathologies feed off each other.
Mutations in the gene for amyloid precursor protein can increase amyloid beta production and lead to plaque formation, which is why some families carry a genetic risk for early-onset Alzheimer’s. But in most cases, the disease emerges from a combination of aging, genetics (particularly a gene variant called APOE4), and environmental factors rather than from a single inherited mutation.
Can Amyloid From the Body Reach the Brain?
This is where the question gets more nuanced. For years, researchers assumed that amyloid beta in the brain was produced locally and stayed local. Newer evidence complicates that picture. Circulating amyloid beta in the bloodstream can cross the blood-brain barrier, the protective layer of cells that normally keeps most blood-borne substances out of brain tissue.
Animal research has shown one potential route: platelets, the small blood cells involved in clotting, carry amyloid beta and can damage the blood-brain barrier’s integrity, increasing its permeability. In mouse studies, platelets from aged Alzheimer’s-model mice increased amyloid deposits in the brains of young, healthy recipient mice and caused learning and memory deficits. The platelets damaged the barrier’s lining cells, effectively opening a door for peripheral amyloid beta to enter the brain and accumulate in the hippocampus, a region critical for memory.
This research is still in animal models, and it specifically involves amyloid beta, the same peptide found in Alzheimer’s plaques. It does not mean that the transthyretin or antibody-fragment proteins from systemic amyloidosis travel to the brain and cause Alzheimer’s. The proteins are structurally different and behave differently. However, it does raise the possibility that amyloid beta produced outside the brain could contribute to Alzheimer’s pathology under certain conditions.
Cognitive Symptoms in Systemic Amyloidosis
People with systemic amyloidosis, particularly the transthyretin form, can experience cognitive and psychological symptoms. Studies have found that anxiety, depression, and cognitive dysfunction are reported in nearly 50% of patients with transthyretin amyloidosis. Symptoms can include difficulty concentrating, reduced energy, social withdrawal, and mild cognitive impairment on screening tests.
These symptoms don’t necessarily mean Alzheimer’s is developing. Amyloid can accumulate in the central nervous system in systemic forms of the disease, and the resulting nerve damage, combined with the stress of chronic illness, can produce cognitive changes that mimic or overlap with early dementia. In at least one documented case, a patient’s cognitive decline and depressive symptoms were initially attributed to a psychiatric disorder before transthyretin amyloidosis was identified as the underlying cause. This highlights how easily the cognitive effects of systemic amyloidosis can be misread.
How Doctors Tell Them Apart
Diagnosing Alzheimer’s now relies on biomarkers that detect amyloid beta plaques and tau tangles specifically. Amyloid PET brain scans can visualize plaque buildup, and a scan is considered positive when it corresponds to at least moderate plaque density combined with a certain stage of tau pathology. In roughly 76% of cognitively healthy individuals, a positive amyloid PET scan reflects the full combination of Alzheimer’s-type changes, not just isolated amyloid deposits.
Systemic amyloidosis, by contrast, is diagnosed through tissue biopsies (often from abdominal fat or an affected organ), blood and urine tests for abnormal proteins, and cardiac imaging. The diagnostic pathways barely overlap. If you have systemic amyloidosis, your doctors are not screening you for Alzheimer’s based on that diagnosis alone, and vice versa.
Different Diseases, Different Treatments
Treatments for Alzheimer’s and systemic amyloidosis both target amyloid, but they go after entirely different proteins using different strategies. The newer Alzheimer’s drugs are monoclonal antibodies designed to bind to amyloid beta in the brain and trigger immune cells called microglia to engulf and break down the plaques. Each approved antibody targets a slightly different form of amyloid beta: some preferentially clear early-stage clumps called protofibrils, while others target a modified form of amyloid beta found only in mature plaques.
Treatments for systemic amyloidosis take a completely different approach. For the transthyretin form, drugs work by stabilizing the transthyretin protein so it doesn’t misfold in the first place, or by silencing the gene that produces it. For the antibody-fragment form, treatment targets the abnormal immune cells producing the problematic protein. None of these systemic treatments have any role in Alzheimer’s, and the Alzheimer’s antibodies have no role in systemic amyloidosis. The shared word “amyloid” in both conditions reflects a common structural feature of misfolded proteins, not a shared disease or a shared treatment target.